Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with crohn's disease?

Diseases of the Colon and Rectum

Volumn 55, Issue 5, 2012, Pages 563-568

  White, Evan C ^a   Melmed, Gil Y ^a   Vasiliauskas, Eric ^a   Dubinsky, Marla ^a   Ippoliti, Andrew ^a   McGovern, Dermot ^a   Targan, Stephan ^a   Fleshner, Phillip ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Abdominal surgery; Crohn's disease; Unplanned hospital readmission

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID; TACROLIMUS; TIOGUANINE; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL SURGERY; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CROHN DISEASE; FEMALE; HEALTH CARE PLANNING; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREOPERATIVE TREATMENT; SCHOOL CHILD; STEROID THERAPY; TREATMENT DURATION; COMPARATIVE STUDY; DOSE RESPONSE; FOLLOW UP; INCIDENCE; LAPAROSCOPY; METHODOLOGY; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CHILD; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LAPAROSCOPY; MALE; MIDDLE AGED; PATIENT DISCHARGE; PATIENT READMISSION; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; YOUNG ADULT;

EID: 84863572276     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e3182468961     Document Type: Article

References (19)

1. Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am. 2007;87:575-585. (Pubitemid 46881077)
2. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483.
3. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241. (Pubitemid 40139240)
4. Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg. 2008;12:1738-1744.
5. Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. Dis Colon Rectum. 2000;43:1141-1145. (Pubitemid 30626148)
6. Post S, Betzler M, von Ditfurth B, Schürmann G, Küppers P, Herfarth C. Risks of intestinal anastomoses in Crohn's disease. Ann Surg. 1991;213:37-42.
7. Alves A, Panis Y, Bouhnik Y, Pocard M, Vicaut E, Valleur P. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum. 2007;50:331-336. (Pubitemid 46393968)
8. Myrelid P, Olaison G, Sjödahl R, Nyström PO, Almer S, Andersson P. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn's disease. Dis Colon Rectum. 2009;52:1387-1394.
9. Tay GS, Binion DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003;134:565-572.
10. Indar AA, Young-Fadok TM, Heppell J, Efron JE. Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients. World J Surg. 2009;33:1049-1052.
11. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther. 2004;19:749-754. (Pubitemid 38496640)
12. Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg. 2008;12:1730-1736.
13. Colombel JF, Loftus EVJr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878-883. (Pubitemid 39090217)
14. Welch HG, Larson EH, Hart LG, Rosenblatt RA. Readmission after surgery in Washington State rural hospitals. Am J Public Health. 1992;82:407-411.
15. Healey MA, Shackford SR, Osler TM, Rogers FB, Burns E. Complications in surgical patients. Arch Surg. 2002;137:611-617.
16. Courtney ED, Ankrett S, McCollum PT. 28-Day emergency surgical re-admission rates as a clinical indicator of performance. Ann R Coll Surg Engl. 2003;85:75-78. (Pubitemid 36372232)
17. Shively EH, Heine MJ, Schell RH, et al. Practicing surgeons lead in quality care, safety, and cost control. Ann Surg. 2004;239:752-760.
18. Kariv Y, Wang W, Senagore AJ, Hammel JP, Fazio VW, Delaney CP. Multivariable analysis of factors associated with hospital readmission after intestinal surgery. Am J Surg. 2006;191:364-371. (Pubitemid 43266007)
19. Kiran RP, Delaney CP, Senagore AJ, Steel M, Garafalo T, Fazio VW. Outcomes and prediction of hospital readmission after intestinal surgery. J Am Coll Surg. 2004;198:877-883. (Pubitemid 38759837)